These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 31406244)
1. FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma. Wang J; Jiang J; Chen H; Wang L; Guo H; Yang L; Xiao D; Qing G; Liu H Oncogene; 2019 Oct; 38(41):6737-6751. PubMed ID: 31406244 [TBL] [Abstract][Full Text] [Related]
2. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Qing G; Li B; Vu A; Skuli N; Walton ZE; Liu X; Mayes PA; Wise DR; Thompson CB; Maris JM; Hogarty MD; Simon MC Cancer Cell; 2012 Nov; 22(5):631-44. PubMed ID: 23153536 [TBL] [Abstract][Full Text] [Related]
3. A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma. Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM Oncogene; 2021 Apr; 40(13):2367-2381. PubMed ID: 33658627 [TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655 [TBL] [Abstract][Full Text] [Related]
5. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival. Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673 [TBL] [Abstract][Full Text] [Related]
6. TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation. Li K; Wang F; Yang ZN; Zhang TT; Yuan YF; Zhao CX; Yeerjiang Z; Cui B; Hua F; Lv XX; Zhang XW; Yu JJ; Liu SS; Yu JM; Shang S; Xiao Y; Hu ZW Nat Commun; 2020 Dec; 11(1):6316. PubMed ID: 33298911 [TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent. Miles MA; Harris MA; Hawkins CJ Apoptosis; 2019 Jun; 24(5-6):404-413. PubMed ID: 30997620 [TBL] [Abstract][Full Text] [Related]
8. ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid. Wu JC; Jiang HM; Yang XH; Zheng HC Cancer Med; 2018 Sep; 7(9):4554-4569. PubMed ID: 30091530 [TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Brockmann M; Poon E; Berry T; Carstensen A; Deubzer HE; Rycak L; Jamin Y; Thway K; Robinson SP; Roels F; Witt O; Fischer M; Chesler L; Eilers M Cancer Cell; 2013 Jul; 24(1):75-89. PubMed ID: 23792191 [TBL] [Abstract][Full Text] [Related]
10. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma. Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554 [No Abstract] [Full Text] [Related]
11. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells. Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626 [TBL] [Abstract][Full Text] [Related]
12. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668 [TBL] [Abstract][Full Text] [Related]
13. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells. Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259 [TBL] [Abstract][Full Text] [Related]
14. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma. Zhou Y; Liu X; Xue J; Liu L; Liang T; Li W; Yang X; Hou X; Fang H J Med Chem; 2020 May; 63(9):4701-4715. PubMed ID: 32267687 [TBL] [Abstract][Full Text] [Related]
15. A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Sottile F; Gnemmi I; Cantilena S; D'Acunto WC; Sala A Oncotarget; 2012 May; 3(5):535-45. PubMed ID: 22619121 [TBL] [Abstract][Full Text] [Related]
16. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. Ren P; Yue M; Xiao D; Xiu R; Gan L; Liu H; Qing G J Pathol; 2015 Jan; 235(1):90-100. PubMed ID: 25142020 [TBL] [Abstract][Full Text] [Related]
19. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615 [TBL] [Abstract][Full Text] [Related]
20. Targeting the Difficult-to-Drug CD71 and MYCN with Gambogic Acid and Vorinostat in a Class of Neuroblastomas. Bishayee K; Habib K; Sadra A; Huh SO Cell Physiol Biochem; 2019; 53(1):258-280. PubMed ID: 31313541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]